JP2024541771A5 - - Google Patents
Info
- Publication number
- JP2024541771A5 JP2024541771A5 JP2024531113A JP2024531113A JP2024541771A5 JP 2024541771 A5 JP2024541771 A5 JP 2024541771A5 JP 2024531113 A JP2024531113 A JP 2024531113A JP 2024531113 A JP2024531113 A JP 2024531113A JP 2024541771 A5 JP2024541771 A5 JP 2024541771A5
- Authority
- JP
- Japan
- Prior art keywords
- modified oligonucleotide
- nucleic acid
- item
- nucleoside
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163283177P | 2021-11-24 | 2021-11-24 | |
| US63/283,177 | 2021-11-24 | ||
| US202163287952P | 2021-12-09 | 2021-12-09 | |
| US63/287,952 | 2021-12-09 | ||
| US202263302976P | 2022-01-25 | 2022-01-25 | |
| US63/302,976 | 2022-01-25 | ||
| US202263339873P | 2022-05-09 | 2022-05-09 | |
| US63/339,873 | 2022-05-09 | ||
| PCT/US2022/080448 WO2023097291A1 (en) | 2021-11-24 | 2022-11-23 | Complement factor b-modulating compositions and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024541771A JP2024541771A (ja) | 2024-11-12 |
| JP2024541771A5 true JP2024541771A5 (cg-RX-API-DMAC7.html) | 2026-06-15 |
Family
ID=86540402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024531113A Pending JP2024541771A (ja) | 2021-11-24 | 2022-11-23 | 補体因子bを調節する組成物及びその使用方法 |
Country Status (14)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4684015A2 (en) | 2023-03-21 | 2026-01-28 | Arrowhead Pharmaceuticals, Inc. | Rnai agents for inhibiting expression of complement factor b (cfb), pharmaceutical compositions thereof, and methods of use |
| WO2025026228A1 (zh) * | 2023-07-28 | 2025-02-06 | 苏州炫景生物科技有限公司 | Cfb抑制剂组合物及其应用 |
| WO2025151250A2 (en) * | 2024-01-09 | 2025-07-17 | Adarx Pharmaceuticals, Inc. | Complement factor b-modulating compositions and methods of use thereof |
| WO2025256564A1 (en) * | 2024-06-12 | 2025-12-18 | Qilu Pharmaceutical Co., Ltd. | iRNA COMPOSITION AND METHOD OF USING SAME |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2305813A3 (en) | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| CA2566286A1 (en) | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same |
| WO2014107763A1 (en) | 2013-01-08 | 2014-07-17 | Benitec Biopharma Limited | Age-related macular degeneration treatment |
| PL3043827T3 (pl) | 2013-09-13 | 2020-03-31 | Ionis Pharmaceuticals, Inc. | Modulatory czynnika b dopełniacza |
| WO2015089368A2 (en) * | 2013-12-12 | 2015-06-18 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
| CR20160554A (es) | 2014-05-01 | 2017-03-07 | Ionis Pharmaceuticals Inc | Composiciones y métodos para modular la expresión del factor b del complemento |
| CN119120476A (zh) | 2017-11-13 | 2024-12-13 | 赛伦斯治疗有限责任公司 | 用于抑制细胞中lpa的表达的核酸 |
| MX2022013606A (es) * | 2020-04-30 | 2023-01-16 | Alnylam Pharmaceuticals Inc | Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas. |
| US20250136977A1 (en) | 2021-09-02 | 2025-05-01 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of complement factor b (cfb) in a cell |
| US20240401045A1 (en) * | 2021-10-01 | 2024-12-05 | Adarx Pharmaceuticals, Inc. | Angiotensinogen-modulating compositions and methods of use thereof |
| AR127477A1 (es) | 2021-10-29 | 2024-01-31 | Alnylam Pharmaceuticals Inc | COMPOSICIONES DE ARNi CONTRA EL FACTOR B DEL COMPLEMENTO (CFB) Y MÉTODOS DE USO DE LAS MISMAS |
-
2022
- 2022-11-23 EP EP22899562.7A patent/EP4437104A4/en active Pending
- 2022-11-23 CA CA3240273A patent/CA3240273A1/en active Pending
- 2022-11-23 US US18/058,664 patent/US12595477B2/en active Active
- 2022-11-23 AU AU2022396536A patent/AU2022396536B2/en active Active
- 2022-11-23 IL IL312928A patent/IL312928A/en unknown
- 2022-11-23 CN CN202280089242.5A patent/CN119256083A/zh active Pending
- 2022-11-23 JP JP2024531113A patent/JP2024541771A/ja active Pending
- 2022-11-23 KR KR1020247020753A patent/KR20240107360A/ko active Pending
- 2022-11-23 WO PCT/US2022/080448 patent/WO2023097291A1/en not_active Ceased
- 2022-11-23 PE PE2024001199A patent/PE20241340A1/es unknown
- 2022-11-23 MX MX2024006368A patent/MX2024006368A/es unknown
- 2022-11-24 TW TW111145061A patent/TW202340463A/zh unknown
-
2024
- 2024-05-23 CL CL2024001561A patent/CL2024001561A1/es unknown
- 2024-05-27 CO CONC2024/0006751A patent/CO2024006751A2/es unknown